A5042534139- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- COVID-19 and healthcare impacts
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
- SARS-CoV-2 and COVID-19 Research
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Platelet Disorders and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Immunodeficiency and Autoimmune Disorders
- Phagocytosis and Immune Regulation
- COVID-19 Clinical Research Studies
- Glioma Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
Gold Coast Hospital
2016-2025
Griffith University
2019-2025
The University of Sydney
2023
Concord Repatriation General Hospital
2023
Gold Coast Health
2017
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus alone in relapsed/refractory multiple myeloma. We provide one additional year follow up and include effect on minimal residual disease clinically relevant subgroups. After 25.4 months up, prolonged progression-free survival (median not reached vs. 17.5 months; hazard ratio, 0.41; 95% confidence interval, 0.31-0.53; P
Abstract The COVID‐19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known cause disproportionately severe disease in cancer, and lymphoma, myeloma chronic lymphocytic leukaemia are likely be at particular risk related COVID‐19. This statement has been developed by consensus among authors from Australia New Zealand. We aim provide supportive guidance clinicians making individual patient decisions during pandemic, periods that...
Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high FL patients harmonize clinical trial populations. The utilization of GELF (GELFc) in routine therapeutic decision- making poorly described. This multicenter retrospective study evaluated patterns GELFc at presentation decision-making newly diagnosed, advanced-stage...
In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard-of-care regimens. a randomized trial, we tested whether similar improvements would be observed was bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen. Transplant-ineligible untreated myeloma were receive VCD or plus (VCDD). A total of 121 randomized: 57 in arm 64 VCDD arm. Baseline characteristics balanced between 2 arms. The median progression-free survival...
Abstract Telomere biology disorders (TBDs) are inherited conditions associated with multisystem manifestations. We describe clinical and functional characterisation of a novel TERT variant. Whole‐genome sequencing was performed along single telomere length analysis ( STELA ). Telomerase activity processivity were assessed. A variant (K710R) detected in patient classic TBD features showing reduced telomerase processivity. Despite evidence, the classified as uncertain significance. have...
Abstract Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B‐cell lymphoma (RR‐DLBCL) based on positive results of the landmark phase II randomised G029365 trial. However, trial many novel therapies RR‐DLBCL have not been replicated routine care cohorts, as patient populations are heterogeneous eligibility increasingly restrictive. We evaluated outcomes from pola ± patients enrolled a compassionate access...
Management practices in early-stage (I/II) follicular lymphoma (FL) are variable and include radiation (RT), systemic therapy, or combined modality therapy (CMT). There is a paucity of data regarding maintenance rituximab this cohort. We conducted an international retrospective study patients with newly diagnosed FL staged positron emission tomography (PET)-computed bone marrow biopsy. Three hundred sixty-five (stage I, n = 221), median age 63 years, treated from 2005-2017 were included,...
Hemotropic mycoplasmas (hemoplasmas) infect animals and humans can lead to clinical syndromes mainly characterized by hemolytic anemia. A novel pathogen, Candidatus Mycoplasma haemohominis, was recently associated with a case of human hemoplasmosis in Europe. Here we report the first detection this pathogen an Australian patient exhibiting persistent fever, anemia, pancytopenia over 10-month period.After exhaustive negative testing for infectious diseases, whole genome sequencing (WGS)...
Summary Infection and lymphopenia are established bendamustine‐related complications. The relationship between severity infection risk, the role of antimicrobial prophylaxis, is not well described. This multicentre retrospective study analysed characteristics prophylaxis in 302 bendamustine‐treated indolent non‐Hodgkin lymphoma patients. Lymphopenia (<1 × 10 9 /L) was near universal time to lymphocyte recovery correlated with cumulative bendamustine dose. No association duration observed....
Antiretroviral therapy (ART) has improved outcomes for human immunodeficiency virus-associated non-Hodgkin lymphoma (HIV-NHL). This is an analysis of 44 patients with HIV Burkitt (HIV-BL) and diffuse large B-cell (HIV-DLBCL) treated in Australia over a 10-year period (2009-2019) during the ART rituximab era. At HIV-NHL diagnosis, majority presenting had adequate CD4 counts undetectable viral load <50 copies/mL. More than 80% received chemotherapy curative intent, rituximab, concurrent...
Abstract High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) relapsed/refractory (RRMM) We report an updated subgroup analysis of POLLUX based on risk. The was determined using fluorescence situ hybridization/karyotyping; patients with high had t (4;14), (14;16), or del17p abnormalities. Minimal residual disease (MRD; 10...
Australia and New Zealand have achieved excellent community control of COVID‐19 infection. In light the imminent vaccination roll out in both countries, representatives from Haematology Society infectious diseases specialists collaborated on this consensus position statement regarding patients with haematological disorders. It is our recommendation that malignancies, some benign disorders, should expedited access to high‐efficacy vaccines, given these are at high risk morbidity mortality...
Background: Lysine-specific demethylase-1 (LSD1) is critical for the self-renewal malignant stem cells and maturation of megakaryocytes, cell central to ET pathogenesis. Bomedemstat an oral LSD1 inhibitor active in mouse models MPNs including improved survival (Kleppe et al. 2015; Jutzi 2018). IMG-7289-CTP-201 ongoing, global, open-label, Phase 2b study bomedemstat taken QD 24+ weeks patients with who are resistant/intolerant at least one standard treatment (NCT04254978). Aims: Key...
Abstract Background Despite recent advances, optimal therapeutic approaches applicable to subpopulations with primary central nervous system (CNS) lymphoma outside of clinical trials remain be determined. Methods We performed a retrospective study immunocompetent, adult patients histologically confirmed diffuse large B‐cell the CNS (PCNSL). 190/204 (93%) (median age: 65) received one five high‐dose methotrexate (HD‐MTX) containing chemotherapy regimens: MPV/Ara‐C (HD‐MTX, procarbazine, and...
Population-based studies have demonstrated a high risk of second cancers, especially the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) primary malignancies (SPM) in Australian relapsed/refractory CLL treated at least two lines therapy, including ibrutinib. From December 2014 to November 2017, 156 were identified from 13 sites enrolled Australasian Lymphoma and Related Diseases Registry, 111 had follow-up data on rates SPM....
Abstract Study Objective The objective of the study is to compare anti‐factor Xa (AXa) level in blood, after arterial and venous line administration equivalent doses enoxaparin for prevention thrombosis extracorporeal blood circuit. Design design a dual centre, prospective, open‐labelled randomized crossover, 7 weeks trial. Setting setting on patient long‐term haemodialysis (HD) or haemodiafiltration (HDF) using high‐flux membrane. Participant There were eight patients HD HDF. Intervention...
Venetoclax, a potent B-cell lymphoma-2 (BCL-2) inhibitor, has demonstrated clinical efficacy in chronic lymphocytic leukemia (CLL). VENICE II is an open-label, single-arm, phase 3b study (NCT02980731) evaluating the impact of venetoclax monotherapy (400 mg once daily) for ≤2 years on health-related quality life (HRQoL) patients with relapsed/refractory CLL. The primary endpoint was mean change global health status (GHS)/quality (QoL) subscale European Organization Research and Treatment...